ProCE Banner Activity

Pooled Analysis of Filgotinib Trials in RA: Incidence and Risk Factors for VTE and MACE

Slideset Download
Conference Coverage
Pooled analysis of 7 phase II/III trials suggests that the investigational JAK inhibitor is associated with low rates of VTE and MACE, with no major safety signals among those with cardiovascular risk factors.

Released: November 13, 2020

Expiration: November 12, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Gilead Sciences, Inc.

Sanofi Genzyme Corp